

Product Data Sheet

Product Name: SD 169
Cat. No.: GC14982

Chemical Properties

Cas. No. 1670-87-7

Chemical Name 1H-indole-5-carboxamide

SMILES NC(C1=CC=C(NC=C2)C2=C1)=O

Formula $C_9H_8N_2O$

M.Wt 160.2


Solubility $\leq 1.4\text{mg/ml}$ in ethanol; 5mg/ml in DMSO; 16mg/ml in dimethyl formamide

Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37°C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request.

Structure



Background

SD 169 (indole-5-carboxamide) is a selective and ATP competitive inhibitor of the MAP kinases p38 α and p38 β [1].

The p38 mitogen-activated protein kinases are a class of mitogen-activated protein kinases (MAPKs)

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

that are responsive to stress stimuli, such as cytokines, ultraviolet irradiation, heat shock, and osmotic shock, and are involved in regulating inflammatory cytokine production, modulating T cell function and cell differentiation, apoptosis and autophagy [1].

SD-169 significantly reduced p38 and HSP60 expression in T cells of the pancreatic beta islets. SD-169 treatment significantly lowered the incidence of diabetes as determined by blood glucose levels. In NOD mice, SD-169 treatment significantly reduced immuno-histochemistry of pancreatic beta islet tissue in CD5+ T cell infiltration. In mildly and moderately hyperglycemic NOD mice, SD-169 (600 mg/kg) treatment lowered blood glucose and improved glucose homeostasis. SD-169 prevented the development and progression of diabetes in NOD mice by inhibiting T cell infiltration and activation, thereby preserving beta cell mass via inhibition of the p38 MAPK signaling pathway. SD 169 also reduced the incidence of diabetes, lowered blood glucose, and improved glucose homeostasis [1]. Gavage administration o SD-169 (30 mg/kg) significantly increased the rate of axonal regeneration in animals with crush injury. SD-169 significantly reduced TNF-mediated primary SC death in culture experiments. SD-169 promoted axonal regeneration through interactions with SC signaling and TNF activity [2].

References:

- [1] Medicherla S, Protter A A, Ma J Y, et al. Preventive and therapeutic potential of p38 α -selective mitogen-activated protein kinase inhibitor in nonobese diabetic mice with Type 1 diabetes[J]. Journal of Pharmacology and Experimental Therapeutics, 2006, 318(1): 99-107.
- [2] Myers R R, Sekiguchi Y, Kikuchi S, et al. Inhibition of p38 MAP kinase activity enhances axonal regeneration[J]. Experimental neurology, 2003, 184(2): 606-614.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA